Nitta Gelatin India Limited (BSE: NITTAGELA) is a BSE-listed specialty gelatin and collagen manufacturer with a market capitalisation of approximately 16.73 billion Indian rupees. Shares gained 5.68 percent to Rs 1,950.60 on the day, with volume of approximately 21,610 shares at an above-average relative volume of 1.30.
Nitta Gelatin India is a joint venture between Nitta Gelatin of Japan and Indian promoters, manufacturing pharmaceutical-grade gelatin, food-grade gelatin and collagen peptides for domestic and international markets. The P/E of 18.21 is attractively low for a specialty food ingredient company with consistent EPS growth.
Key Stock Highlights
- BSE Symbol: NITTAGELA
- Market Cap: Approximately 16.73 billion INR.
- Price: Rs 1,950.60, up 5.68 percent on the day.
- Volume: 21,610 shares; relative volume 1.30 -- above average.
- P/E Ratio: 18.21 times trailing earnings.
- EPS (diluted TTM): Rs 107.11 per share.
- EPS Growth TTM YoY: +15.85 percent -- steady growth.
- Dividend Yield: 0.34 percent.
- Analyst Rating: No coverage.
Company Overview and Business Model
Nitta Gelatin India Limited manufactures gelatin, collagen peptides and di-calcium phosphate at its production facility in Thrissur, Kerala, using bovine-sourced raw materials. Pharmaceutical-grade gelatin is used in the manufacture of hard and soft gelatin capsules, which are among the world's most widely used drug delivery formats. Food-grade gelatin is used in confectionery, dairy products and food processing applications.
The company is a joint venture with Nitta Gelatin Inc. of Japan, providing access to Japanese manufacturing technology, quality standards and market relationships. Japanese gelatin companies maintain among the highest quality standards globally, and the Nitta technology transfer enables Nitta Gelatin India to supply to international pharmaceutical clients with demanding quality requirements.
Collagen peptides represent a growing revenue stream as the nutraceutical and functional food market expands globally. Collagen supplementation has become mainstream in beauty, joint health and sports nutrition applications, creating demand for food-grade hydrolysed collagen that Nitta Gelatin India is positioned to supply.
Financial Analysis
The P/E of 18.21 at an EPS of Rs 107.11 is attractively low for a specialty gelatin and collagen manufacturer with a consistent earnings growth track record. Specialty food ingredient companies with pharmaceutical-grade certifications typically trade at P/E multiples in the 20 to 35 times range, suggesting Nitta Gelatin India may be modestly undervalued relative to sector peers.
The 15.85 percent EPS growth is steady and reflects consistent demand growth across the pharmaceutical capsule gelatin and collagen peptide segments. This kind of steady, moderate earnings growth with a low P/E and a small dividend yield is the profile of a quality compounder that has not yet attracted broad market attention.
The 5.68 percent price gain on above-average relative volume of 1.30 is a constructive signal for a small-cap gelatin company. The above-average volume combined with a meaningful price gain and steady earnings growth creates a positive investment picture, though the absence of analyst coverage means investors must conduct independent primary source research.
Technical Trends
A 5.68 percent gain on 1.30 relative volume is a technically positive event for Nitta Gelatin India. For a small-cap specialty chemicals company with a low P/E and consistent earnings growth, this kind of above-average volume gaining day is consistent with discovery buying -- where new investors find a quality compounder that has not yet attracted mainstream attention.
The low P/E of 18.21 provides a valuation cushion that limits downside risk for investors. Even if earnings growth moderates somewhat, the current valuation level is modest by specialty chemicals standards, suggesting limited permanent capital risk at current price levels.
Nitta Gelatin India's price performance is most likely driven by quarterly earnings disclosures and any demand updates from the pharmaceutical capsule gelatin or collagen peptide segments. The Japanese parent company relationship and pharmaceutical-grade certifications are stable competitive attributes that are unlikely to change rapidly.
Sector and Market Context
The pharmaceutical gelatin market is driven by the global demand for hard and soft gelatin capsules, which remain the dominant oral drug delivery format for both prescription and over-the-counter medicines. Growing pharmaceutical production volumes globally, particularly in India and China, create consistent base demand for pharmaceutical-grade gelatin.
Collagen peptides for nutraceutical and functional food applications represent one of the fastest-growing segments in the global gelatin market. Consumers in developed markets are increasingly purchasing collagen supplements for skin, joint and bone health applications, driving demand growth for food-grade collagen peptide producers.
India's pharmaceutical manufacturing expansion provides a growing domestic customer base for pharmaceutical-grade gelatin. Indian pharmaceutical companies producing capsule formulations for both domestic and export markets require consistent, quality-assured gelatin supply, creating a stable domestic revenue base for Nitta Gelatin India.
Investor Insights
Nitta Gelatin India presents a quality compounder investment case with a low P/E, consistent 15.85 percent EPS growth, Japanese technology backing and exposure to pharmaceutical gelatin and collagen peptide markets. The above-average volume gain suggests the stock may be gaining broader investor awareness.
At 18.21 times earnings with modest but consistent growth and a small dividend yield, Nitta Gelatin India offers a relatively safe entry point for investors seeking specialty food ingredients exposure. The absence of analyst coverage means the stock may be less efficiently priced than covered peers, potentially creating opportunity for investors willing to conduct their own research.
This article is for informational purposes only and does not constitute personal financial advice. Investors should conduct their own research and consult a SEBI-registered investment adviser before making investment decisions.
Frequently Asked Questions
Q: What does Nitta Gelatin India produce?
A: Nitta Gelatin India produces pharmaceutical-grade gelatin for capsule manufacturing, food-grade gelatin for food processing, and collagen peptides for nutraceutical and functional food applications.
Q: Why is the P/E of 18.21 considered low for this company?
A: Specialty food ingredient companies with pharmaceutical certifications typically trade at 20 to 35 times earnings. Nitta Gelatin India's 18.21 P/E appears modest relative to sector peers, potentially indicating undervaluation.
Q: What is the Nitta Japan relationship?
A: Nitta Gelatin India is a joint venture with Nitta Gelatin Inc. of Japan, which provides manufacturing technology, quality standards and international market relationships to the Indian operation.
Q: What are collagen peptides used for?
A: Collagen peptides are hydrolysed collagen proteins used in nutritional supplements for skin, joint and bone health; in sports nutrition for muscle recovery; and in functional food and beverage products globally.